The Argatroban and tissue-type plasminogen activator stroke study: Final results of a pilot safety study

Stroke

Volumn 43, Issue 3, 2012, Pages 770-775

  Barreto, Andrew D ^a   Alexandrov, Andrei V ^b   Lyden, Pat ^c   Lee, Jessica ^d   Martin Schild, Sheryl ^e   Shen, Loren ^a   Wu, Tzu Ching ^a   Sisson, April ^b   Pandurengan, Renganayaki ^a   Chen, Zhongxue ^a   Rahbar, Mohammad H ^a   Balucani, Clotilde ^b,f   Barlinn, Kristian ^b   Sugg, Rebecca M ^g   Garami, Zsolt ^h   Tsivgoulis, Georgios ^b,i   Gonzales, Nicole R ^a   Savitz, Sean I ^a   Mikulik, Robert ^j   Demchuk, Andrew M ^k   Grotta, James C ^a   more..

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PERUGIA   (Italy)

^g UNIVERSITY OF MISSISSIPPI   (United States)

^h HOUSTON METHODIST HOSPITAL   (United States)

ⁱ DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^j ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^k UNIVERSITY OF CALGARY   (Canada)

more..

Author keywords

acute stroke; anticoagulation; Argatroban; thrombin inhibition; thrombolysis

Indexed keywords

ARGATROBAN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTICOAGULATION; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN HERNIA; BRAIN ISCHEMIA; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DOPPLER ECHOGRAPHY; DRUG SAFETY; FEMALE; HEART ARREST; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PILOT STUDY; PRIORITY JOURNAL; RECANALIZATION; RESPIRATORY FAILURE; SEIZURE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTITHROMBINS; BRAIN ISCHEMIA; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; CEREBRAL VEINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PILOT PROJECTS; PIPECOLIC ACIDS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84857646331     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.625574     Document Type: Article

References (29)

1. Walenga JM. An overview of the direct thrombin inhibitor Argatroban. Pathophysiol Haemost Thromb. 2002;32(suppl 3):9-14.
2. Tanaka KA, Szlam F, Katori N, Sato N, Vega JD, Levy JH. The effects of Argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg. 2004;99:1283-1289.
3. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of Argatroban versus heparin as adjunct to tissue plasminogen activator (tPA) in acute myocardial infarction: Myocardial Infarction with Novastan and tPA (MINT) study. J Am Coll Cardiol. 1999;33:1879-1885.
4. Moledina M, Chakir M, Gandhi PJ. A synopsis of the clinical uses of Argatroban. J Thromb Thrombolysis. 2001;12:141-149.
5. Wykrzykowska JJ, Kathiresan S, Jang IK. Clinician update: direct thrombin inhibitors in acute coronary syndromes. J Thromb Thrombolysis. 2003;15:47-57.
6. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 1990;67:1552-1561.
7. Kawai H, Umemura K, Nakashima M. Effect of Argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol. 1995;69:143-148.
8. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, Chopp M. Extension of the therapeutic window for recombinant tissue plasminogen activator with Argatroban in a rat model of embolic stroke. Stroke. 2001;32:2635-2640.
9. Tamao Y, Kikumoto R. Effect of Argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. Semin Thromb Hemost. 1997;23:523-530.
10. Tanaka YS. Therapeutic effect of Argatroban (MD-805), antithrombotic agent, in the acute stage of cerebral thrombosis. J Clin Ther Med. 1987;3:133-142.
11. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor Argatroban in acute cerebral thrombosis. Semin Thromb Hemost. 1997;23:531-534.
12. La Monte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke. 2004;35:1677-1682.
13. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study group. N Engl J Med. 1995;333:1581-1587.
14. Hacke W, Brott T, Caplan L, Meier D, Fieschi C, von Kummer R, et al. Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology. 1999;53:S3-14.
15. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study investigators. Lancet. 1998;352:1245-1251.
16. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation. 2001;103:2897-2902.
17. Demchuk AM, Burgin WS, Christou I, Felberg RA, Barber PA, Hill MD, et al. Thrombolysis In Brain Ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator. Stroke. 2001;32:89-93.
18. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV. Is the benefit of early recanalization sustained at 3 months? A prospective cohort study. Stroke. 2003;34:695-698.
19. Alexandrov AV, Demchuk AM, Burgin WS, Robinson DJ, Grotta JC. Ultrasound-enhanced thrombolysis for acute ischemic stroke: Phase I. Findings of the CLOTBUST trial. J Neuroimaging. 2004;14:113-117.
20. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862-867.
21. Sugg RM, Pary JK, Uchino K, Baraniuk S, Shaltoni HM, Gonzales NR, et al. Argatroban tPA stroke study: study design and results in the first treated cohort. Arch Neurol. 2006;63:1057-1062.
22. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
23. Tsivgoulis G, Sharma VK, Lao AY, Malkoff MD, Alexandrov AV. Validation of transcranial Doppler with computed tomography angiography in acute cerebral ischemia. Stroke. 2007;38:1245-1249.
24. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30:2280-2284.
25. Ciccone A, Abraha I, Santilli I. Glycoprotein IIb-IIIa inhibitors for acute ischemic stroke. Stroke. 2007;38:1113-1114.
26. Ueshima S, Fukao H, Okada K, Matsuo O. The effect of Argatroban on injured endothelial cells by thrombin. Blood Coagul Fibrinolysis. 2000;11:631-639.
27. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004;351:2170-2178.
28. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38:948-954.
29. Bhatia R, Hill MD, Shobha N, Menon B, Bal S, Kochar P, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41:2254-2258.